Integer Holdings Corporation Reports Third Quarter 2026 Results
EXHIBIT 99.1 Integer Holdings Corporation Reports Third Quarter 2026 Results PLANO, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended October 2, 2026.
As previously announced, given Integer’s pending acquisition by an affiliate of investment funds managed by KKR (the “Transaction”) pursuant to the Agreement and Plan of Merger, dated as of August 2, 2026, by and among Integer, Armstrong Parent, Inc. (“Parent”), and Armstrong Bidco, Inc. (the “Merger Agreement”), the Company is not providing a financial outlook and will not host a conference call to discuss its third quarter 2026 financial results. On September 29, 2026, the Company received early termination of the waiting period under the Hart-Scott- Rodino Antitrust Improvements Act of 1976, as amended, and on October 21, 2026, Integer's stockholders approved the adoption of the Merger Agreement. The Transaction is anticipated to close by the end of 2026, subject to the satisfaction or waiver of the remaining customary closing conditions specified in the Merger Agreement, including receipt of required regulatory approvals.
EBITDA, adjusted EBITDA, Adjusted operating income, Adjusted net income, and Adjusted EPS are non-GAAP financial measures. Please see (a) “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures. Refer to Tables A, B and C at the end of this release for reconciliations of adjusted amounts to the closest corresponding GAAP financial measures.
Organic sales change is a non-GAAP financial measure. Please see “Notes Regarding Non-GAAP Financial Information” for additional information (a) regarding our use of non-GAAP financial measures and refer to Table D at the end of this release for a reconciliation of these amounts to the closest corresponding GAAP financial measures.
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMOs) in the world, serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. As a strategic partner of choice, we advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation. The company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
In addition to our results reported in accordance with generally accepted accounting principles in the United States of America (“GAAP”), we provide adjusted net income, adjusted EPS, earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted EBITDA, adjusted operating income, and organic sales change. Unless otherwise indicated, all financial metrics presented reflect continuing operations only.
Adjusted net income and adjusted EPS consist of GAAP income (loss) from continuing operations and diluted EPS from continuing operations, respectively, adjusted for the following to the extent occurring during the period: (i) amortization of intangible assets, (ii) certain legal expenses; (iii) restructuring and restructuring-related charges; (iv) acquisition and integration costs; (v) other general expenses; (vi) ERP implementation, (vii) (gain) loss on equity investments; (viii) extinguishment of debt charges, (ix) debt conversion inducement expense; (x) European Union medical device regulation incremental charges; (xi) inventory step-up amortization; (xii) unusual, or infrequently occurring items; (xiii) the income tax provision (benefit) related to these adjustments and (xiv) certain tax items that are outside the normal tax provision for the period. Adjusted EPS is calculated by dividing adjusted net income by adjusted weighted average shares.
The weighted average shares used to calculate diluted EPS in accordance with GAAP includes dilution, when applicable, resulting from the potential conversion of our 2028 Convertible Notes and 2030 Convertible Notes (collectively, the “Convertible Notes”). In connection with the issuance of the Convertible Notes, we entered into capped call contracts which are expected to reduce the potential dilution on our common stock in connection with any conversion of the Convertible Notes, subject to a cap. Adjusted weighted average shares consists of GAAP weighted average shares used to calculate diluted EPS, including, when applicable, dilutive common stock equivalents that were excluded from weighted average shares used to calculate diluted EPS as their inclusion would be anti- dilutive and excluding, when applicable, dilution resulting from the potential conversion of our Convertible Notes expected to be offset by the capped call contracts.
EBITDA is calculated by adding back interest expense, provision for income taxes, depreciation expense, and amortization expense from intangible assets and financing leases, to income (loss) from continuing operations, which is the most directly comparable GAAP financial measure. Adjusted EBITDA consists of EBITDA plus adding back stock-based compensation and the same adjustments as listed above except for items (i), (viii), (xiii) and (xiv). Adjusted operating income consists of operating income adjusted for the same items listed above except for items (vii), (viii), (ix), (xiii) and (xiv).
Organic sales change is reported sales growth adjusted to remove the impact of foreign currency, the contribution of acquisitions and the strategic exit of the Portable Medical market. To calculate the impact of foreign currency on sales growth rates, we convert any sale made in a foreign currency by converting current period sales into prior period sales using the exchange rate in effect at that time and then compare the two, negating any effect foreign currency had on our transactional revenue. For contribution of acquisitions, we exclude the impact on the growth rate attributable to the contribution of acquisitions in all periods where there were no comparable sales. For the strategic exit of the Portable Medical market, we exclude the impact on the growth rate attributable to Portable Medical sales for all periods presented.
We believe that the presentation of adjusted net income, adjusted EPS, EBITDA, adjusted EBITDA, adjusted operating income, and organic sales change, provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations. In addition to the performance measures identified above, we believe that net total debt and leverage ratio provide meaningful measures of liquidity and a useful basis for assessing our ability to fund our activities, including the financing of acquisitions and debt repayments. Net total debt is calculated as total principal amount of debt outstanding less cash and cash equivalents. We calculate leverage ratio as net total debt divided by adjusted EBITDA for the trailing 4 quarters.
Some of the statements contained in this communication and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include, but are not limited to, statements relating to: the completion of the Transaction on anticipated terms and timing, or at all, including obtaining regulatory approvals and satisfying other conditions to the completion of the Transaction; potential litigation relating to the Transaction that has been or could be instituted against the parties to the Merger Agreement, or their respective directors, managers, or officers, including the effects of any outcomes related thereto; our goals, plans, and strategic initiatives; long-term growth prospects; maximizing value for our stockholders; other events, conditions or developments that will or may occur in the future; and the timing of any of the foregoing. You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “forecast,” “outlook,” “assume,” “potential” or “continue” or variations or the negative counterparts of these terms or other comparable terminology. These statements are only predictions and are not guarantees of future performance, and investors should not place undue reliance on forward-looking statements as predictive of future results. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and by others contained throughout this communication.
Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements regarding the Transaction. All such forward-looking statements are based upon current plans, estimates, expectations, opportunities and ambitions that are subject to risks, uncertainties, assumptions, and other important factors, many of which are beyond the control of the Company, that could cause actual results to differ materially from those expressed in such forward-looking statements. Key factors that could cause actual results to differ materially include, but are not limited to, the expected timing and likelihood of completion of the Transaction, including the timing, receipt and terms and conditions of any required governmental and regulatory approvals; the occurrence of any event, change or other circumstances that could give rise to the termination of the Transaction; the risk that the parties may not be able to satisfy the conditions to the Transaction in a timely manner or at all; risks related to disruption of management time from ongoing business operations due to the Transaction; the risk that any announcements relating to the Transaction could have adverse effects on the market price of the Company’s common stock; the risk that the Transaction and its announcement could have an adverse effect on the parties’ business relationships and business generally, including the ability of the Company to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers, and on their operating results and businesses generally; the risk of unforeseen or unknown liabilities; customer, regulatory and other stakeholder approvals and support; the risk of unexpected future capital expenditures; the risk of potential litigation relating to the Transaction that has been or could be instituted against the Company or its directors and/or officers; the risk associated with third-party contracts containing material consent, anti-assignment, transfer or other provisions that may be related to the Transaction which are not waived or otherwise satisfactorily resolved; significant costs, or expenses incurred in connection with the Transaction; Parent’s ability to obtain the necessary financing arrangements set forth in the commitment letters received in connection with the Transaction; certain restrictions contained in the Merger Agreement that may impact the Company’s ability to pursue certain business opportunities or strategic transactions; the risk of various events that could disrupt operations, including pandemics, epidemics or other public health crises or severe weather (such as droughts, floods, avalanches and earthquakes), cybersecurity attacks, security threats and governmental response to them, and technological changes; the risks of labor disputes, changes in labor costs and labor difficulties; and the risks resulting from other effects of industry, market, economic, legal or legislative, political or regulatory conditions outside of the Company’s control. All such factors are difficult to predict and are beyond our control, including those detailed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the Securities and Exchange Commission (the “SEC”) on February 23, 2026, the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended July 3, 2026, which was filed with the SEC on August 4, 2026, the Company’s definitive proxy statement filed with the SEC on September 14, 2026, as supplemented, and other documents subsequently filed by the Company with the SEC. The Company’s forward-looking statements are based on assumptions that the Company believes to be reasonable but that may not prove to be accurate. Other unpredictable factors not discussed in this communication could also have material adverse effects on forward-looking statements. The Company does not assume an obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements speak only as of the date hereof.
Condensed Consolidated Balance Sheets - Unaudited October 2, December 31, (in thousands) 2026 2025 ────────────────────────────────────────────────────────────────────────────── ASSETS Current assets: Cash and cash equivalents $ 14,135 $ 17,161 Accounts receivable, net 345,072 346,079 Inventories 278,591 253,739 Contract assets 119,297 112,546 Prepaid expenses and other current 44,297 40,572 assets Total current assets 801,392 770,097 Property, plant and equipment, net 535,133 536,427 Goodwill 1,100,799 1,110,908 Other intangible assets, net 770,089 825,435 Deferred income taxes 8,938 8,994 Operating lease assets 82,586 98,437 Financing lease assets 55,491 37,109 Other long-term assets 39,509 23,170 Total assets $ 3,393,937 $ 3,410,577 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 111,003 $ 113,130 Operating lease liabilities 8,359 9,099 Accrued expenses and other current 81,763 109,812 liabilities Total current liabilities 201,125 232,041 Long-term debt 1,219,247 1,185,179 Deferred income taxes 113,596 116,327 Operating lease liabilities 67,371 81,899 Financing lease liabilities 49,577 28,578 Other long-term liabilities 16,622 19,910 Total liabilities 1,667,538 1,663,934 Stockholders’ equity: Common stock 35 35 Additional paid-in capital 761,271 771,223 Treasury stock (110,334 ) (76,872 ) Retained earnings 1,049,144 994,055 Accumulated other comprehensive 26,283 58,202 income Total stockholders’ equity 1,726,399 1,746,643 Total liabilities and stockholders’ $ 3,393,937 $ 3,410,577 equity
Condensed Consolidated Statements of Cash Flows - Unaudited (in thousands) Nine Months Cash flows from Ended operating October 2, September 26, activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 55,089 $ 54,200 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 103,899 95,158 amortization Debt related charges included in 4,910 5,239 interest expense Debt conversion inducement — 46,681 expense Stock-based 17,273 17,467 compensation Non-cash fixed asset 7,141 — impairment Non-cash lease 7,283 7,583 expense Non-cash (gains) losses 1,395 (223 ) on equity investments Contingent consideration (1,179 ) (660 ) fair value adjustment Other non-cash 4,043 804 losses Deferred income 17 4,082 taxes Gain on sale of discontinued — (46 ) operations Changes in operating assets and liabilities, net of acquisitions:
Accounts (98 ) (46,793 ) receivable Inventories (28,474 ) (12,241 ) Prepaid expenses and (4,110 ) 117 other assets Contract assets (7,255 ) (2,106 ) Accounts 2,137 3,187 payable Accrued expenses and (29,421 ) (22,359 ) other liabilities Income taxes (11,589 ) (9,357 ) payable Net cash provided by 121,061 140,733 operating activities Cash flows from investing activities: Acquisition of property, plant (67,181 ) (63,555 ) and equipment Purchase of equity and (14,043 ) — other investments Acquisitions, — (170,872 ) net Other investing 126 (835 ) activities Net cash used in investing (81,098 ) (235,262 ) activities Cash flows from financing activities: Principal payments of — (657,697 ) long-term debt Proceeds from issuance of convertible — 977,500 notes, net of discount Proceeds from revolving 221,000 301,000 credit facility Payments of revolving (191,000 ) (427,000 ) credit facility Purchase of — (71,000 ) capped calls Payment of debt (38 ) (1,386 ) issuance costs Proceeds from the exercise of — 3,644 stock options Tax withholdings related to net share (10,419 ) (16,812 ) settlements of restricted stock unit awards Repurchases of (50,000 ) — common stock Principal payments on (6,558 ) (4,165 ) finance leases Other financing (5,163 ) 1,194 activities Net cash provided by (used in) (42,178 ) 105,278 financing activities Effect of foreign currency exchange (811 ) 1,652 rates on cash and cash equivalents Net increase (decrease) in (3,026 ) 12,401 cash and cash equivalents Cash and cash equivalents, 17,161 46,543 beginning of period Cash and cash equivalents, $ 14,135 $ 58,944 end of period
Income from continuing operations (GAAP) per diluted share amounts are calculated in accordance with GAAP using weighted average shares for diluted EPS. The per share amounts for the adjustments in the table (a) above and adjusted net income are calculated using adjusted weighted average shares. The following table provides a reconciliation from GAAP weighted average shares for diluted EPS to non-GAAP adjusted weighted average shares.
The difference between pre-tax and net of tax amounts is the estimated tax impact related to the respective adjustment. Net of tax amounts are (b) computed using a 21% U.S. tax rate, and the statutory tax rates applicable in foreign tax jurisdictions, as adjusted for the existence of net operating losses (“NOLs”). Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%. Certain legal expenses associated with non-ordinary course legal matters. Amounts for the third quarter and first nine months of 2026 (c) include $0.7 million and $2.5 million, respectively, of expense incurred in connection with the Company’s defense of a securities class action lawsuit. We initiate discrete restructuring programs primarily to realign resources to better serve our customers and markets, improve operational efficiency and capabilities, and lower operating costs or improve profitability. Depending on the program, restructuring charges may include termination benefits, contract termination, facility closure and other exit and disposal costs. Restructuring-related expenses are directly related to the program and may include retention (d) bonuses, accelerated depreciation, consulting expense and costs to transfer manufacturing operations among our facilities. Amounts for the third quarter and first nine months of 2026 include $2.2 million and $5.0 million, respectively, relating to our global manufacturing alignment restructuring initiative. In addition, the third quarter and first nine months of 2026 includes $0.6 million and $3.0 million, respectively, related to an organizational realignment to enhance execution of our strategy through dedicated focus on growth and operational excellence. Acquisition and integration costs are incremental costs that are directly related to a business or asset acquisition. These costs may (e) include, among other things, professional, consulting and other fees, system integration costs, and fair value adjustments relating to contingent consideration. Other general expenses are discrete transactions occurring sporadically and affect period-over-period comparisons. The Company recorded fixed asset impairment charges during the third quarter and first nine months of 2026 of $1.2 million and $7.1 million, respectively, which were (f) primarily due to revised expectations regarding the future use of certain fixed assets, and expense of $2.9 million and $4.4 million, respectively, related to termination benefits from actions to align labor with manufacturing volumes. The third quarter and first nine months of 2025 include $6.2 million related to termination benefits from actions to align labor with manufacturing volumes. These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will (g) require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance. Expenses for 2026 were primarily included in SG&A. Amounts reflect our share of equity method investee (gains) losses (h) including unrealized appreciation/depreciation of the underlying interests of the investee. The charges represent incremental costs of complying with European (i) Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. Other adjustments include costs which impact period-to-period comparability and do not represent the underlying ongoing results of our business. For 2025 and 2026, amounts include costs associated with (j) leadership transitions, strategic projects, a stockholder activist matter, the Company’s strategic review and the Transaction, and a cyber incident. Other adjustments includes the following expenses (in millions):
Tax adjustments include changes to uncertain tax benefits and associated interest for all periods presented, and for 2026 also reflect nondeductible transaction costs. In addition, included in the (k) amount for the first nine months of 2025 is the write off of a deferred tax asset for $4.1 million related to a portion of the unamortized original issue discount due to the partial exchange of the 2028 Convertible Notes. Loss on extinguishment of debt consists of accelerated write-offs of (l) unamortized deferred debt issuance costs and discounts, which are included in interest expense. Debt conversion inducement expense relates to the partial exchange of (m) the 2028 Convertible Notes and is recorded within Other loss, net in the Condensed Consolidated Statements of Operations.
Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures.
(a) Excludes amounts included in Restructuring and restructuring-related charges. Total stock-based compensation expense less amounts included in (b) Restructuring and restructuring-related charges, ERP implementation, and Other adjustments.
Table D: Organic Sales Change Reconciliation (% Change) GAAP Impact of Impact of Non-GAAP Reported Foreign Strategic Organic Growth Currency(a) Exits and Change Acquisitions(a) QTD Change (3Q 2026 vs. 3Q 2025) Product Line Cardio & Vascular (5.1)% (0.1)% 0.1% (5.1)% Cardiac Rhythm Management & 3.9% —% —% 3.9% Neuromodulation Other Markets (49.7)% —% (28.3)% (21.4)% Total Sales (3.9)% —% (1.7)% (2.2)% YTD Change (9M 2026 vs. 9M 2025) Product Line Cardio & Vascular (2.2)% 0.2% 0.3% (2.7)% Cardiac Rhythm Management & 3.3% —% —% 3.3% Neuromodulation Other Markets (46.8)% —% (30.9)% (15.9)% Total Sales (2.0)% 0.1% (1.3)% (0.8)%
Sales growth has been adjusted to exclude the impact of foreign (a) currency exchange rate fluctuations, when applicable, and strategic exits and acquisitions.
Full text with the tables
EXHIBIT 99.1
Integer Holdings Corporation Reports Third Quarter 2026 Results
PLANO, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation
(NYSE:ITGR) today announced results for the three months ended October 2, 2026.
ThirdQuarter 2026 Highlights(compared to Third Quarter 2025, except as noted)
As previously announced, given Integer’s pending acquisition by an affiliate of
investment funds managed by KKR (the “Transaction”) pursuant to the Agreement
and Plan of Merger, dated as of August 2, 2026, by and among Integer, Armstrong
Parent, Inc. (“Parent”), and Armstrong Bidco, Inc. (the “Merger Agreement”), the
Company is not providing a financial outlook and will not host a conference call
to discuss its third quarter 2026 financial results. On September 29, 2026, the
Company received early termination of the waiting period under the Hart-Scott-
Rodino Antitrust Improvements Act of 1976, as amended, and on October 21, 2026,
Integer's stockholders approved the adoption of the Merger Agreement. The
Transaction is anticipated to close by the end of 2026, subject to the
satisfaction or waiver of the remaining customary closing conditions specified
in the Merger Agreement, including receipt of required regulatory approvals.
Discussion of Product Line Third Quarter 2026 Sales
Su…
Fi…
Re…
(d…
in
th…
ex…
per Thr… Oct… Sep… Nine Octo… Sep…
sh… Mon… 2, 26, QTD Mon… 2, 26, YTD
da… End… 2026 2025 Chan… End… 2026 2025 Chan…
──────────────────────────────────────────────────────────────────────────────
Op… $ 28,… $ 56,… (50… $ 94,6… $ 165… (42.…
in… %
In…
fr… $ 14,… $ 39,… (62… $ 55,0… $ 54,… 1.6%
co… %
op…
Di…
EPS (61…
fr… $ 0.43 $ 1.11 % $ 1.60 $ 1.52 5.3%
co…
op…
EB… $ 61,… $ 88,… (30… $ 194,… $ 207… (6.3…
%
Ad… $ 87,… $ 105… (17… $ 267,… $ 296… (9.6…
EB… %
Ad… (22…
op… $ 66,… $ 85,… % $ 200,… $ 238… (15.…
in…
Ad… (26…
net $ 46,… $ 63,… % $ 142,… $ 163… (13.…
in…
Ad… $ 1.34 $ 1.79 (25… $ 4.14 $ 4.64 (10.…
EP… %
EBITDA, adjusted EBITDA, Adjusted operating income, Adjusted net
income, and Adjusted EPS are non-GAAP financial measures. Please see
(a) “Notes Regarding Non-GAAP Financial Information” for additional
information regarding our use of non-GAAP financial measures. Refer to
Tables A, B and C at the end of this release for reconciliations of
adjusted amounts to the closest corresponding GAAP financial measures.
Summ…
Prod…
Line
Resu…
(dol… Three Octob… Septe…
in Months 2, 26, QTD Organic
thou… Ended 2026 2025 Change Change…
──────────────────────────────────────────────────────────────────────────────
Prod…
Line
Sales
Card…
& $ 263,0… $ 277,1… (5.1)% (5.1)%
Vasc…
Card…
Rhyt…
Mana… 175,8… 169,1… 3.9% 3.9%
&
Neur…
Other 10,750 21,386 (49.7… (21.4)%
Mark…
Total $ 449,6… $ 467,6… (3.9)% (2.2)%
Sales
Nine
Months
Ended
Octob… Septe… YTD Organ…
2, 26, Change Chang…
2026 2025
Prod…
Line
Sales
Card… (2.2)
& $ 805,1… $ 822,8… % (2.7) %
Vasc…
Card…
Rhyt…
Mana… 517,8… 501,4… 3.3% 3.3%
&
Neur…
Other 30,423 57,203 (46.8) (15.9)
Mark… % %
Total $ 1,353… $ 1,381… (2.0) (0.8) %
Sales %
Organic sales change is a non-GAAP financial measure. Please see “Notes
Regarding Non-GAAP Financial Information” for additional information
(a) regarding our use of non-GAAP financial measures and refer to Table D
at the end of this release for a reconciliation of these amounts to the
closest corresponding GAAP financial measures.
About Integer ®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device
contract development and manufacturing organizations (CDMOs) in the world,
serving the cardio and vascular, neuromodulation, and cardiac rhythm management
markets. As a strategic partner of choice, we advance the goals of our medical
device customers through industry-leading engineering and manufacturing, with a
relentless commitment to quality, service, and innovation. The company's brands
include Greatbatch Medical® and Lake Region Medical®. Additional information is
available at www.integer.net.
Investor Relations:
Kristen Stewart
551-337-3973
[email protected]
Notes Regarding Non-GAAP Financial Information
In addition to our results reported in accordance with generally accepted
accounting principles in the United States of America (“GAAP”), we provide
adjusted net income, adjusted EPS, earnings before interest, taxes, depreciation
and amortization (“EBITDA”), adjusted EBITDA, adjusted operating income, and
organic sales change. Unless otherwise indicated, all financial metrics
presented reflect continuing operations only.
Adjusted net income and adjusted EPS consist of GAAP income (loss) from
continuing operations and diluted EPS from continuing operations, respectively,
adjusted for the following to the extent occurring during the period: (i)
amortization of intangible assets, (ii) certain legal expenses; (iii)
restructuring and restructuring-related charges; (iv) acquisition and
integration costs; (v) other general expenses; (vi) ERP implementation, (vii)
(gain) loss on equity investments; (viii) extinguishment of debt charges, (ix)
debt conversion inducement expense; (x) European Union medical device regulation
incremental charges; (xi) inventory step-up amortization; (xii) unusual, or
infrequently occurring items; (xiii) the income tax provision (benefit) related
to these adjustments and (xiv) certain tax items that are outside the normal tax
provision for the period. Adjusted EPS is calculated by dividing adjusted net
income by adjusted weighted average shares.
The weighted average shares used to calculate diluted EPS in accordance with
GAAP includes dilution, when applicable, resulting from the potential conversion
of our 2028 Convertible Notes and 2030 Convertible Notes (collectively, the
“Convertible Notes”). In connection with the issuance of the Convertible Notes,
we entered into capped call contracts which are expected to reduce the potential
dilution on our common stock in connection with any conversion of the
Convertible Notes, subject to a cap. Adjusted weighted average shares consists
of GAAP weighted average shares used to calculate diluted EPS, including, when
applicable, dilutive common stock equivalents that were excluded from weighted
average shares used to calculate diluted EPS as their inclusion would be anti-
dilutive and excluding, when applicable, dilution resulting from the potential
conversion of our Convertible Notes expected to be offset by the capped call
contracts.
EBITDA is calculated by adding back interest expense, provision for income
taxes, depreciation expense, and amortization expense from intangible assets and
financing leases, to income (loss) from continuing operations, which is the most
directly comparable GAAP financial measure. Adjusted EBITDA consists of EBITDA
plus adding back stock-based compensation and the same adjustments as listed
above except for items (i), (viii), (xiii) and (xiv). Adjusted operating income
consists of operating income adjusted for the same items listed above except for
items (vii), (viii), (ix), (xiii) and (xiv).
Organic sales change is reported sales growth adjusted to remove the impact of
foreign currency, the contribution of acquisitions and the strategic exit of the
Portable Medical market. To calculate the impact of foreign currency on sales
growth rates, we convert any sale made in a foreign currency by converting
current period sales into prior period sales using the exchange rate in effect
at that time and then compare the two, negating any effect foreign currency had
on our transactional revenue. For contribution of acquisitions, we exclude the
impact on the growth rate attributable to the contribution of acquisitions in
all periods where there were no comparable sales. For the strategic exit of the
Portable Medical market, we exclude the impact on the growth rate attributable
to Portable Medical sales for all periods presented.
We believe that the presentation of adjusted net income, adjusted EPS, EBITDA,
adjusted EBITDA, adjusted operating income, and organic sales change, provides
important supplemental information to management and investors seeking to
understand the financial and business trends relating to our financial condition
and results of operations. In addition to the performance measures identified
above, we believe that net total debt and leverage ratio provide meaningful
measures of liquidity and a useful basis for assessing our ability to fund our
activities, including the financing of acquisitions and debt repayments. Net
total debt is calculated as total principal amount of debt outstanding less cash
and cash equivalents. We calculate leverage ratio as net total debt divided by
adjusted EBITDA for the trailing 4 quarters.
Cautionary Statement Regarding Forward-Looking Statements
Some of the statements contained in this communication and other written and
oral statements made from time to time by us and our representatives are not
statements of historical or current fact. As such, they are “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended and
are subject to the safe harbor created thereby under the Private Securities
Litigation Reform Act of 1995. We have based these forward-looking statements on
our current expectations, and these statements are subject to known and unknown
risks, uncertainties and assumptions. Forward-looking statements include, but
are not limited to, statements relating to: the completion of the Transaction on
anticipated terms and timing, or at all, including obtaining regulatory
approvals and satisfying other conditions to the completion of the Transaction;
potential litigation relating to the Transaction that has been or could be
instituted against the parties to the Merger Agreement, or their respective
directors, managers, or officers, including the effects of any outcomes related
thereto; our goals, plans, and strategic initiatives; long-term growth
prospects; maximizing value for our stockholders; other events, conditions or
developments that will or may occur in the future; and the timing of any of the
foregoing. You can identify forward-looking statements by terminology such as
“may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,”
“believes,” “estimates,” “predicts,” “projects,” “forecast,” “outlook,”
“assume,” “potential” or “continue” or variations or the negative counterparts
of these terms or other comparable terminology. These statements are only
predictions and are not guarantees of future performance, and investors should
not place undue reliance on forward-looking statements as predictive of future
results. Actual events or results may differ materially from those stated or
implied by these forward-looking statements. In evaluating these statements and
our prospects, you should carefully consider the factors set forth below. All
forward-looking statements attributable to us or persons acting on our behalf
are expressly qualified in their entirety by these cautionary factors and by
others contained throughout this communication.
Forward-looking statements by their nature address matters that are, to
different degrees, uncertain, such as statements regarding the Transaction. All
such forward-looking statements are based upon current plans, estimates,
expectations, opportunities and ambitions that are subject to risks,
uncertainties, assumptions, and other important factors, many of which are
beyond the control of the Company, that could cause actual results to differ
materially from those expressed in such forward-looking statements. Key factors
that could cause actual results to differ materially include, but are not
limited to, the expected timing and likelihood of completion of the Transaction,
including the timing, receipt and terms and conditions of any required
governmental and regulatory approvals; the occurrence of any event, change or
other circumstances that could give rise to the termination of the Transaction;
the risk that the parties may not be able to satisfy the conditions to the
Transaction in a timely manner or at all; risks related to disruption of
management time from ongoing business operations due to the Transaction; the
risk that any announcements relating to the Transaction could have adverse
effects on the market price of the Company’s common stock; the risk that the
Transaction and its announcement could have an adverse effect on the parties’
business relationships and business generally, including the ability of the
Company to retain customers and retain and hire key personnel and maintain
relationships with their suppliers and customers, and on their operating results
and businesses generally; the risk of unforeseen or unknown liabilities;
customer, regulatory and other stakeholder approvals and support; the risk of
unexpected future capital expenditures; the risk of potential litigation
relating to the Transaction that has been or could be instituted against the
Company or its directors and/or officers; the risk associated with third-party
contracts containing material consent, anti-assignment, transfer or other
provisions that may be related to the Transaction which are not waived or
otherwise satisfactorily resolved; significant costs, or expenses incurred in
connection with the Transaction; Parent’s ability to obtain the necessary
financing arrangements set forth in the commitment letters received in
connection with the Transaction; certain restrictions contained in the Merger
Agreement that may impact the Company’s ability to pursue certain business
opportunities or strategic transactions; the risk of various events that could
disrupt operations, including pandemics, epidemics or other public health crises
or severe weather (such as droughts, floods, avalanches and earthquakes),
cybersecurity attacks, security threats and governmental response to them, and
technological changes; the risks of labor disputes, changes in labor costs and
labor difficulties; and the risks resulting from other effects of industry,
market, economic, legal or legislative, political or regulatory conditions
outside of the Company’s control. All such factors are difficult to predict and
are beyond our control, including those detailed in the Company’s Annual Report
on Form 10-K for the fiscal year ended December 31, 2025, which was filed with
the Securities and Exchange Commission (the “SEC”) on February 23, 2026, the
Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended July 3,
2026, which was filed with the SEC on August 4, 2026, the Company’s definitive
proxy statement filed with the SEC on September 14, 2026, as supplemented, and
other documents subsequently filed by the Company with the SEC. The Company’s
forward-looking statements are based on assumptions that the Company believes to
be reasonable but that may not prove to be accurate. Other unpredictable factors
not discussed in this communication could also have material adverse effects on
forward-looking statements. The Company does not assume an obligation to update
any forward-looking statements, except as required by applicable law. These
forward-looking statements speak only as of the date hereof.
Condensed Consolidated Balance
Sheets - Unaudited October 2, December 31,
(in thousands) 2026 2025
──────────────────────────────────────────────────────────────────────────────
ASSETS
Current assets:
Cash and cash equivalents $ 14,135 $ 17,161
Accounts receivable, net 345,072 346,079
Inventories 278,591 253,739
Contract assets 119,297 112,546
Prepaid expenses and other current 44,297 40,572
assets
Total current assets 801,392 770,097
Property, plant and equipment, net 535,133 536,427
Goodwill 1,100,799 1,110,908
Other intangible assets, net 770,089 825,435
Deferred income taxes 8,938 8,994
Operating lease assets 82,586 98,437
Financing lease assets 55,491 37,109
Other long-term assets 39,509 23,170
Total assets $ 3,393,937 $ 3,410,577
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable $ 111,003 $ 113,130
Operating lease liabilities 8,359 9,099
Accrued expenses and other current 81,763 109,812
liabilities
Total current liabilities 201,125 232,041
Long-term debt 1,219,247 1,185,179
Deferred income taxes 113,596 116,327
Operating lease liabilities 67,371 81,899
Financing lease liabilities 49,577 28,578
Other long-term liabilities 16,622 19,910
Total liabilities 1,667,538 1,663,934
Stockholders’ equity:
Common stock 35 35
Additional paid-in capital 761,271 771,223
Treasury stock (110,334 ) (76,872 )
Retained earnings 1,049,144 994,055
Accumulated other comprehensive 26,283 58,202
income
Total stockholders’ equity 1,726,399 1,746,643
Total liabilities and stockholders’ $ 3,393,937 $ 3,410,577
equity
Cond…
Cons…
Stat…
of
Oper…
-
Unau…
(in
thou…
exce…
per Three Octob… Septe… Nine Octob… Septem…
share Months 2, 26, Months 2, 26,
data) Ended 2026 2025 Ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
Sales $ 449,6… $ 467,6… $ 1,353… $ 1,381,…
Cost
of 348,1… 341,5… 1,029… 1,005,…
sales
Gross 101,5… 126,1… 324,0… 375,630
prof…
Oper…
expe…
Sell…
gene… 54,147 50,451 170,5… 154,534
and
admi…
Rese…
deve… 13,528 10,949 41,049 39,390
and
engi…
Rest…
and 5,677 8,321 17,886 16,377
other
char…
Total
oper… 73,352 69,721 229,4… 210,301
expe…
Oper… 28,209 56,439 94,606 165,329
inco…
Inte… 9,701 9,367 29,570 33,926
expe…
(Gai…
loss
on (31 ) (50 ) 1,395 (223 )
equi…
inve…
Other
loss, 1,027 1,130 2,487 53,037
net
Inco…
from
cont… 17,512 45,992 61,154 78,589
oper…
befo…
taxes
Prov…
(ben…
for 2,534 6,314 6,065 24,367
inco…
taxes
Inco…
from 14,978 39,678 55,089 54,222
cont…
oper…
Loss
from
disc…
oper… — — — (22 )
net
of
tax
Net $ 14,978 $ 39,678 $ 55,089 $ 54,200
inco…
Basic
earn…
per
shar…
Inco…
from $ 0.44 $ 1.13 $ 1.62 $ 1.56
cont…
oper…
Loss
from $ — $ — $ — $ —
disc…
oper…
Basic
earn… $ 0.44 $ 1.13 $ 1.62 $ 1.56
per
share
Dilu…
earn…
per
shar…
Inco…
from $ 0.43 $ 1.11 $ 1.60 $ 1.52
cont…
oper…
Loss
from $ — $ — $ — $ —
disc…
oper…
Dilu…
earn… $ 0.43 $ 1.11 $ 1.60 $ 1.52
per
share
Weig…
aver…
shar…
outs…
Basic 34,027 35,081 34,106 34,689
Dilu… 34,604 35,608 34,394 35,755
Condensed
Consolidated
Statements of
Cash Flows -
Unaudited
(in thousands) Nine Months
Cash flows from Ended
operating October 2, September 26,
activities: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 55,089 $ 54,200
Adjustments to
reconcile net
income to
net cash
provided by
operating
activities:
Depreciation
and 103,899 95,158
amortization
Debt related
charges
included in 4,910 5,239
interest
expense
Debt conversion
inducement — 46,681
expense
Stock-based 17,273 17,467
compensation
Non-cash fixed
asset 7,141 —
impairment
Non-cash lease 7,283 7,583
expense
Non-cash
(gains) losses 1,395 (223 )
on equity
investments
Contingent
consideration (1,179 ) (660 )
fair value
adjustment
Other non-cash 4,043 804
losses
Deferred income 17 4,082
taxes
Gain on sale of
discontinued — (46 )
operations
Changes in
operating
assets and
liabilities,
net of
acquisitions:
Accounts (98 ) (46,793 )
receivable
Inventories (28,474 ) (12,241 )
Prepaid
expenses and (4,110 ) 117
other assets
Contract assets (7,255 ) (2,106 )
Accounts 2,137 3,187
payable
Accrued
expenses and (29,421 ) (22,359 )
other
liabilities
Income taxes (11,589 ) (9,357 )
payable
Net cash
provided by 121,061 140,733
operating
activities
Cash flows from
investing
activities:
Acquisition of
property, plant (67,181 ) (63,555 )
and
equipment
Purchase of
equity and (14,043 ) —
other
investments
Acquisitions, — (170,872 )
net
Other investing 126 (835 )
activities
Net cash used
in investing (81,098 ) (235,262 )
activities
Cash flows from
financing
activities:
Principal
payments of — (657,697 )
long-term debt
Proceeds from
issuance of
convertible — 977,500
notes, net of
discount
Proceeds from
revolving 221,000 301,000
credit facility
Payments of
revolving (191,000 ) (427,000 )
credit facility
Purchase of — (71,000 )
capped calls
Payment of debt (38 ) (1,386 )
issuance costs
Proceeds from
the exercise of — 3,644
stock
options
Tax
withholdings
related to net
share (10,419 ) (16,812 )
settlements of
restricted
stock unit
awards
Repurchases of (50,000 ) —
common stock
Principal
payments on (6,558 ) (4,165 )
finance leases
Other financing (5,163 ) 1,194
activities
Net cash
provided by
(used in) (42,178 ) 105,278
financing
activities
Effect of
foreign
currency
exchange (811 ) 1,652
rates on cash
and cash
equivalents
Net increase
(decrease) in (3,026 ) 12,401
cash and cash
equivalents
Cash and cash
equivalents, 17,161 46,543
beginning of
period
Cash and cash
equivalents, $ 14,135 $ 58,944
end of period
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
… T… O… Se…
… M… 2, 26,
… E… 2… 20…
──────────────────────────────────────────────────────────────────────────────
N… P… N… P…
P… of D… P… of D…
T… S… T… S…
…
…
… $ 1… $ 14… $ 0.… $ 45… $ 39… $ 1.…
…
…
…
…
… 1… 12… 0.… 16… 13… 0.…
…
…
…
… 8… 655 0.… 181 144 —
…
…
…
… 4… 3,… 0.… 2,… 2,… 0.…
…
…
…
… 1… 82 — 1,… 1,… 0.…
…
…
…
… 4… 3,… 0.… 6,… 4,… 0.…
…
… 3… 3,… 0.… — — —
…
…
…
… (… ) (24 ) — (50 ) (39 ) —
…
…
…
… 45 35 — 183 145 —
…
… 8… 6,… 0.… 2,… 1,… 0.…
…
… — 779 0.… — 107 —
…
…
… $ 5… $ 46… $ 1.… $ 75… $ 63… $ 1.…
…
…
N…
M…
E…
O… S…
2, 2…
2… 2…
N… P… N… P…
P… of D… P… of D…
T… S… T… S…
…
…
… $ 6… $ 55… $ 1.… $ 78… $ 54… $ 1.…
…
…
…
…
… 4… 38… 1.… 47… 38… 1.…
…
…
…
… 2… 2,… 0.… 292 231 0.…
…
…
…
… 1… 8,… 0.… 6,… 5,… 0.…
…
…
…
… 1… 1,… 0.… 8,… 6,… 0.…
…
…
…
… 1… 10… 0.… 6,… 4,… 0.…
…
… 1… 9,… 0.… — — —
…
…
…
… 1… 1,… 0.… (2… ) (1… ) —
…
…
…
…
… — — — 867 685 0.…
…
…
…
… — — — 46… 46… 1.…
…
…
…
… 3… 307 0.… 695 549 0.…
…
… 1… 13… 0.… 3,… 2,… 0.…
…
… — 1,… 0.… — 4,… 0.…
…
…
… $ 1… $ 14… $ 4.… $ 19… $ 16… $ 4.…
…
…
Income from continuing operations (GAAP) per diluted share amounts are
calculated in accordance with GAAP using weighted average shares for
diluted EPS. The per share amounts for the adjustments in the table
(a) above and adjusted net income are calculated using adjusted weighted
average shares. The following table provides a reconciliation from GAAP
weighted average shares for diluted EPS to non-GAAP adjusted weighted
average shares.
Three
Months Nine Months
Ended September Ended September
October 2, 26, October 2, 26,
2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Weighted
average
shares
for 34,604 35,608 34,394 35,755
diluted
EPS
(GAAP)
Less:
2028
Converti…
Notes (244 ) (261 ) (90 ) (430 )
capped
call
options
impact
Adjusted
weighted
average 34,360 35,347 34,304 35,325
shares
(non-GAA…
The difference between pre-tax and net of tax amounts is the estimated
tax impact related to the respective adjustment. Net of tax amounts are
(b) computed using a 21% U.S. tax rate, and the statutory tax rates
applicable in foreign tax jurisdictions, as adjusted for the existence
of net operating losses (“NOLs”). Expenses that are not deductible for
tax purposes (i.e. permanent tax differences) are added back at 100%.
Certain legal expenses associated with non-ordinary course legal
matters. Amounts for the third quarter and first nine months of 2026
(c) include $0.7 million and $2.5 million, respectively, of expense
incurred in connection with the Company’s defense of a securities class
action lawsuit.
We initiate discrete restructuring programs primarily to realign
resources to better serve our customers and markets, improve
operational efficiency and capabilities, and lower operating costs or
improve profitability. Depending on the program, restructuring charges
may include termination benefits, contract termination, facility
closure and other exit and disposal costs. Restructuring-related
expenses are directly related to the program and may include retention
(d) bonuses, accelerated depreciation, consulting expense and costs to
transfer manufacturing operations among our facilities. Amounts for the
third quarter and first nine months of 2026 include $2.2 million and
$5.0 million, respectively, relating to our global manufacturing
alignment restructuring initiative. In addition, the third quarter and
first nine months of 2026 includes $0.6 million and $3.0 million,
respectively, related to an organizational realignment to enhance
execution of our strategy through dedicated focus on growth and
operational excellence.
Acquisition and integration costs are incremental costs that are
directly related to a business or asset acquisition. These costs may
(e) include, among other things, professional, consulting and other fees,
system integration costs, and fair value adjustments relating to
contingent consideration.
Other general expenses are discrete transactions occurring sporadically
and affect period-over-period comparisons. The Company recorded fixed
asset impairment charges during the third quarter and first nine months
of 2026 of $1.2 million and $7.1 million, respectively, which were
(f) primarily due to revised expectations regarding the future use of
certain fixed assets, and expense of $2.9 million and $4.4 million,
respectively, related to termination benefits from actions to align
labor with manufacturing volumes. The third quarter and first nine
months of 2025 include $6.2 million related to termination benefits
from actions to align labor with manufacturing volumes.
These adjustments represent direct and incremental costs incurred in
connection with our implementation of a new global enterprise resource
planning ("ERP") solution and related IT transition costs. An
implementation of this scale is a significant undertaking and will
(g) require substantial time and attention of management and key employees.
The associated costs do not represent normal and recurring operating
expenses and will be inconsistent in amounts and frequency making it
difficult to contribute to a meaningful evaluation of our operating
performance. Expenses for 2026 were primarily included in SG&A.
Amounts reflect our share of equity method investee (gains) losses
(h) including unrealized appreciation/depreciation of the underlying
interests of the investee.
The charges represent incremental costs of complying with European
(i) Union medical device regulations for previously registered products and
primarily include charges for contractors supporting the project and
other direct third-party expenses.
Other adjustments include costs which impact period-to-period
comparability and do not represent the underlying ongoing results of
our business. For 2025 and 2026, amounts include costs associated with
(j) leadership transitions, strategic projects, a stockholder activist
matter, the Company’s strategic review and the Transaction, and a cyber
incident. Other adjustments includes the following expenses (in
millions):
Three October Septemb… Nine October Septem…
Months 2, 26, Months 2, 26,
Ended 2026 2025 Ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
Leader…
transi… $ — $ 1.0 $ 1.5 $ 1.7
costs
Strate… 1.8 0.7 2.6 2.1
projec…
Stockh…
activi… 0.1 — 3.9 —
matter
Strate…
review 6.9 — 8.2 —
and
Transa…
Cyber
incide… 0.5 — 1.2 —
costs
Tax adjustments include changes to uncertain tax benefits and
associated interest for all periods presented, and for 2026 also
reflect nondeductible transaction costs. In addition, included in the
(k) amount for the first nine months of 2025 is the write off of a deferred
tax asset for $4.1 million related to a portion of the unamortized
original issue discount due to the partial exchange of the 2028
Convertible Notes.
Loss on extinguishment of debt consists of accelerated write-offs of
(l) unamortized deferred debt issuance costs and discounts, which are
included in interest expense.
Debt conversion inducement expense relates to the partial exchange of
(m) the 2028 Convertible Notes and is recorded within Other loss, net in
the Condensed Consolidated Statements of Operations.
Please see “Notes Regarding Non-GAAP Financial Information” for additional
information regarding our use of non-GAAP financial measures.
Table
B:
Adjust…
Operat…
Income
Reconc… Three October Septemb… Nine October Septem…
(in Months 2, 26, Months 2, 26,
thousa… Ended 2026 2025 Ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
Operat…
income $ 28,209 $ 56,439 $ 94,606 $ 165,329
(GAAP)
Adjust…
Amorti…
of 15,749 16,249 47,716 47,220
intang…
assets
Certain
legal 828 181 2,967 292
expens…
Restru…
and 4,666 2,749 10,911 6,426
restru…
charges
Acquis…
and 102 1,372 1,717 8,121
integr…
costs
Other
general 4,176 6,247 12,322 6,253
expens…
ERP 3,947 — 12,221 —
implem…
Medical
device 45 183 389 695
regula…
Other 8,568 2,476 17,485 3,749
adjust…
Adjust…
operat… $ 66,290 $ 85,896 $ 200,334 $ 238,085
income
(non-G…
Table
C:
EBIT…
and
Adju…
EBIT…
Reco… Three Octob… Septe… Nine Octob… Septem…
(in Months 2, 26, Months 2, 26,
thou… Ended 2026 2025 Ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
Inco…
from
cont… $ 14,978 $ 39,678 $ 55,089 $ 54,222
oper…
(GAA…
Inte… 9,701 9,367 29,570 33,926
expe…
Prov…
(ben…
for 2,534 6,314 6,065 24,367
inco…
taxes
Depr… 16,697 15,562 50,783 44,588
Amor…
of
inta…
asse… 17,653 17,478 53,116 50,570
and
fina…
leas…
EBIT… 61,563 88,399 194,6… 207,673
(non…
Stoc… 4,052 4,341 13,886 16,691
comp…
Cert…
legal 828 181 2,967 292
expe…
Rest…
and 4,666 2,749 10,911 6,426
rest…
char…
Acqu…
and 102 1,372 1,717 8,121
inte…
costs
Other
gene… 4,176 6,247 12,322 6,253
expe…
ERP 3,947 — 12,221 —
impl…
(Gai…
loss
on (31 ) (50 ) 1,395 (223 )
equi…
inve…
Debt
conv… — — — 46,681
indu…
expe…
Medi…
devi… 45 183 389 695
regu…
Other 8,568 2,476 17,485 3,749
adju…
Adju…
EBIT… $ 87,916 $ 105,8… $ 267,9… $ 296,358
(non…
(a) Excludes amounts included in Restructuring and restructuring-related
charges.
Total stock-based compensation expense less amounts included in
(b) Restructuring and restructuring-related charges, ERP implementation,
and Other adjustments.
Table D: Organic
Sales Change
Reconciliation (%
Change)
GAAP Impact of Impact of Non-GAAP
Reported Foreign Strategic Organic
Growth Currency(a) Exits and Change
Acquisitions(a)
QTD Change (3Q 2026
vs. 3Q 2025)
Product Line
Cardio & Vascular (5.1)% (0.1)% 0.1% (5.1)%
Cardiac Rhythm
Management & 3.9% —% —% 3.9%
Neuromodulation
Other Markets (49.7)% —% (28.3)% (21.4)%
Total Sales (3.9)% —% (1.7)% (2.2)%
YTD Change (9M 2026
vs. 9M 2025)
Product Line
Cardio & Vascular (2.2)% 0.2% 0.3% (2.7)%
Cardiac Rhythm
Management & 3.3% —% —% 3.3%
Neuromodulation
Other Markets (46.8)% —% (30.9)% (15.9)%
Total Sales (2.0)% 0.1% (1.3)% (0.8)%
Sales growth has been adjusted to exclude the impact of foreign
(a) currency exchange rate fluctuations, when applicable, and strategic
exits and acquisitions.
Table E: Net Total Debt Reconciliation October 2, December 31,
(in thousands) 2026 2025
──────────────────────────────────────────────────────────────────────────
Total debt $ 1,219,247 $ 1,185,179
Add: Debt discounts and deferred 18,037 22,105
issuance costs included in Total debt
Total principal amount of debt 1,237,284 1,207,284
outstanding
Less: Cash and cash equivalents 14,135 17,161
Net Total Debt (Non-GAAP) $ 1,223,149 $ 1,190,123